Seeking Ways to Extend Progression-Free Survival for Patients with Multiple Myeloma
March 5th 2019New data presented at this year’s American Society of Hematology Annual Meeting showed that adding DARZALEX® (daratumumab) to standard of care multiple myeloma therapies may extend survival and achieve levels of minimal residual disease not previously seen.
Read More